Read our latest press releases, hear our most recent media appearances, and see which upcoming events we are attending.
Subscribe to our social channels to ensure you get our updates, news and announcements as and when they happen.
Lipid nanoparticles (LNPs) are recognised as a leading delivery platform following clinical success in vaccine and therapeutic applications. Medicines Discovery Catapult (MDC) has built a preclinical platform to evaluate LNPs against two major challenges in the field. In this blog, Lead Scientist, Dr Phil Auckland, presents a case study of this workflow using intravenously administered LNPs encapsulating mRNA, which differentially target four major liver cell types.
Opening new avenues for RNA therapeutics through a preclinical screening and optimisation platform. In this blog, Lead Scientist Dr Phil Auckland describes how applying this platform to a library of 4,500 lipid nanoparticle (LNP) formulations enabled the identification of novel candidates with desirable mechanistic properties and in vivo functionality. Furthermore, we show that integrating multiple in vitro readouts can enhance prediction and thereby improve translation.
The BIO International Convention is being held in San Diego on the 22 to 25 June 2026. MDC are co-exhibiting with the UK Pavilion on Booth 2221, Ground Floor. Come and meet the team onsite to hear more, or find us on the partnering app to book a meeting with us onsite.
UK Biotech Day is taking place on the 27 and 28 May in London, at the Radisson Hotel & Conference Centre MDC’s will be in attendance, find us on the partnering app to book a meeting with us onsite.
Sleep and circadian Technologies in Mental Health: Translating Evidence into Mental Health Solutions
MDC are participation in the Kadans Oncology Summit 2026 a major international event dedicated to oncology, on the 4 June 2026. Don’t miss Gayle Marshall and Marc Daigneault, who will be participating in the programme at the event.
See how we can help support you with your next drug discovery project.
Speak to us
